SG11201500439RA - Vaccine compositions for prevention against dengue virus infection - Google Patents

Vaccine compositions for prevention against dengue virus infection

Info

Publication number
SG11201500439RA
SG11201500439RA SG11201500439RA SG11201500439RA SG11201500439RA SG 11201500439R A SG11201500439R A SG 11201500439RA SG 11201500439R A SG11201500439R A SG 11201500439RA SG 11201500439R A SG11201500439R A SG 11201500439RA SG 11201500439R A SG11201500439R A SG 11201500439RA
Authority
SG
Singapore
Prior art keywords
virus infection
dengue virus
vaccine compositions
prevention against
against dengue
Prior art date
Application number
SG11201500439RA
Inventor
Jiansheng Yao
Yves Girerd-Chambaz
Isabelle Legastelois
Nathalie Mantel
VéRONIQUE BARBAN
Jean Lang
Bruno Guy
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of SG11201500439RA publication Critical patent/SG11201500439RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201500439RA 2012-07-24 2013-07-24 Vaccine compositions for prevention against dengue virus infection SG11201500439RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305908 2012-07-24
EP12305911 2012-07-25
PCT/EP2013/065669 WO2014016362A1 (en) 2012-07-24 2013-07-24 Vaccine compositions for prevention against dengue virus infection

Publications (1)

Publication Number Publication Date
SG11201500439RA true SG11201500439RA (en) 2015-02-27

Family

ID=48856641

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500439RA SG11201500439RA (en) 2012-07-24 2013-07-24 Vaccine compositions for prevention against dengue virus infection

Country Status (15)

Country Link
US (1) US20150265695A1 (en)
EP (1) EP2877207A1 (en)
JP (1) JP2015524422A (en)
KR (1) KR20150036593A (en)
CN (1) CN104812408A (en)
AU (1) AU2013295016A1 (en)
BR (1) BR112015001313A2 (en)
CA (1) CA2878599A1 (en)
GT (1) GT201500005A (en)
HK (1) HK1212905A1 (en)
MX (1) MX2015000446A (en)
PE (1) PE20150356A1 (en)
PH (1) PH12014502875A1 (en)
SG (1) SG11201500439RA (en)
WO (1) WO2014016362A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102389908B1 (en) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 Compositions and methods for dengue virus chimeric constructs in vaccines
EP3010536A4 (en) * 2013-06-21 2016-11-30 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TW201620546A (en) * 2014-09-02 2016-06-16 賽諾菲巴斯德公司 Vaccine compositions
CN106687590B (en) * 2014-09-11 2021-08-03 Vlp治疗公司 Yellow fever virus-like particles
EP3236997A4 (en) 2014-12-22 2018-05-30 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017023839A1 (en) 2015-08-03 2017-02-09 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
FI3355915T3 (en) * 2015-09-29 2024-01-12 Boehringer Ingelheim Animal Health Usa Inc Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
US11690903B2 (en) 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
BR112021003962A2 (en) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. unit dose of dengue vaccine and its administration

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (en) 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa INJECTABLE MULTIPHASIC EMULSIONS
FR2649013B1 (en) 1989-07-03 1991-10-25 Seppic Sa VACCINES AND VECTORS OF FLUID ACTIVE INGREDIENTS CONTAINING METABOLIZABLE OIL
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
IL131600A0 (en) 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
CA2368790A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
JP2002540170A (en) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ Attenuated dengue type 2 virus vaccine
CN1384877B (en) * 1999-08-02 2010-10-27 惠氏 Rescue of mumps virus from cDNA
EP1263965B1 (en) 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulent, immunogenic flavivirus chimeras
PT1159968E (en) 2000-05-30 2008-11-20 Univ Mahidol Attenuated strains of dengue virus and their use in a vaccine composition
AT410634B (en) 2001-02-21 2003-06-25 Franz X Dr Heinz ATTENUATED LIFE VACCINE
JP2005518332A (en) 2001-05-23 2005-06-23 デンドレオン コーポレイション Conjugates activated by cell surface proteases and their therapeutic use
EP1401859B1 (en) * 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
WO2003010197A2 (en) 2001-07-25 2003-02-06 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
DK2338508T3 (en) * 2002-05-03 2018-05-28 The Government Of The Us Secretary Department Of Health And Human Services rDEN3 / 4delta30 (ME), rDEN2 / 4delta30 (ME) or rDEN1 / 4delta30 (ME) recombinant chimeric Dengue virus containing a 30 nucleotide deletion (delta30) in a section of the 3 'untranslated region of Dengue type 4 genome, where The 30-nucleotide deletion corresponds to the TL2 hairpin structure
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
CN1852734B (en) * 2003-09-17 2010-12-01 杜克大学 Consensus/ancestral immunogens
KR20080018271A (en) * 2005-06-17 2008-02-27 사노피 파스퇴르 Dengue serotype 2 attenuated strain
BRPI0613328A2 (en) * 2005-06-17 2011-01-04 Sanofi Pasteur live attenuated dengue-1 virus strain, immunogenic composition, vaccine composition, isolated nucleic acid, isolated polyprotein and polyprotein fragment
AR054822A1 (en) 2005-07-07 2007-07-18 Sanofi Pasteur ADMISSION IMMUNE EMULSION
BRPI0614265A2 (en) 2005-08-10 2011-03-22 Acambis Inc use of a yellow fever virus vaccine and a chimeric flavivirus vaccine and kit containing such vaccines
CU23586A1 (en) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa EMULSION OIL IN THERMOREVERSIBLE WATER
FR2903605A1 (en) 2006-07-12 2008-01-18 Sanofi Pasteur Sa IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2906724B1 (en) 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
FR2909286B1 (en) 2006-12-01 2012-06-08 Sanofi Pasteur IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE
US8591916B2 (en) * 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
WO2009134717A1 (en) * 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (en) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
WO2011013097A2 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
WO2011062625A2 (en) * 2009-11-18 2011-05-26 The Board Of Regents Of The University Of Texas System Physicochemical (pcp) based consensus sequences and uses thereof
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
MX2012012681A (en) * 2010-05-21 2012-12-17 Univ Pittsburgh Universal dengue virus sequences and methods of use.
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
KR20150036592A (en) * 2012-07-24 2015-04-07 사노피 파스퇴르 Vaccine compositions

Also Published As

Publication number Publication date
WO2014016362A1 (en) 2014-01-30
CA2878599A1 (en) 2014-01-30
HK1212905A1 (en) 2016-06-24
EP2877207A1 (en) 2015-06-03
KR20150036593A (en) 2015-04-07
GT201500005A (en) 2015-10-13
PH12014502875A1 (en) 2015-02-23
CN104812408A (en) 2015-07-29
AU2013295016A1 (en) 2015-01-29
MX2015000446A (en) 2015-03-12
US20150265695A1 (en) 2015-09-24
BR112015001313A2 (en) 2017-08-01
JP2015524422A (en) 2015-08-24
PE20150356A1 (en) 2015-03-20

Similar Documents

Publication Publication Date Title
HK1212905A1 (en) Vaccine compositions for prevention against dengue virus infection
HK1212906A1 (en) Vaccine compositions
HK1209646A1 (en) Nasal influenza vaccine composition
EP2834265A4 (en) Methods and compositions for dengue virus epitopes
PL2647387T3 (en) Vaccine Composition
IL229307A0 (en) Inactivated dengue virus vaccine
EP2825196A4 (en) Adjuvant and vaccine compositions
IL237431A0 (en) Immunogenic compositions
HK1206986A1 (en) Prophylactic/therapeutic agent for influenza virus infection
EP2912060A4 (en) Compositions and methods for inhibiting pathogen infection
EP2931310A4 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
SG11201502221WA (en) Novel attenuated dengue virus strains for vaccine application
IL236476A0 (en) Compositions and methods for treating or preventing pneumo virus infection and associated diseases
SG11201510617WA (en) Methods and compositions for dengue virus vaccines
KR101501876B9 (en) Composition for preventing or treating influenza virus infection comprising xylitol
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus
HK1201283A1 (en) Influenza c virus and vaccine
HK1209140A1 (en) Bovine influenza c virus compositions
GB201215184D0 (en) Therapeutic virus
HK1209647A1 (en) Dengue virus vaccine composition
EP2749287A4 (en) Influenza virus infection inhibitor
AU2013369626A1 (en) Dengue virus vaccine composition
AU2012905097A0 (en) Agents and methods for inhibiting virus infection